FDA Rejects Sunscreen TEAs, Plans Public Hearing On Ingredient Review
This article was originally published in The Rose Sheet
Executive Summary
FDA announces that it has found data insufficient to affirm the safety of two of the eight pending time-and-extent applications for sunscreen actives – amiloxate and diethylhexyl butamido triazone, marketed under the trade names NeoHeliopan and Uvasorb HEB. The agency invites the public and manufacturers, to submit further information in support of the actives’ safety.
You may also be interested in...
Reps Prep Sunscreen Filter Legislation; FDA Frustrated By Backlog
Without swift FDA action on eight sunscreen filters pending review, legislators intend to introduce a bill to alter the agency’s sunscreen approval process. House members questioned FDA Center for Drug Evaluation and Research Director Janet Woodcock on the status of the applications, some of which have been under agency review for more than 10 years.
Women’s Voices For The Earth Will Keep After CIR, Salon Worker Safety In 2024
Women’s Voices for the Earth continues to call attention to cosmetic ingredients’ potential health impacts on users including salon workers, while pushing the Cosmetic Ingredient Review to consider a wider variety of safety information in its assessment work.
Regulatory Acceptance Of Non-Animal Test Methods Holding Back Cosmetics Innovation
“Companies can innovate right now, and they have confidence in these tools, these [non-animal] approaches, and they feel they can put these products on the market safely,” said Erin Hill, CEO and president of the International Collaboration on Cosmetics Safety. “The holdup is that they can’t register these new products, because there’s a lack of confidence in the regulatory community.”